# US 2003/0215849 A1 · PDPK1s as modifiers of the p53 pathway and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215849 A1
- Document ID: US20030215849A1
- Status: Published application
- Kind: A1
- Application number: 10/376,554
- Filed: 2003-02-28
- Published: 2003-11-20
- Earliest claimed: 2002-03-01
- Inventors: Marcia Belvin; Helen Francis-Lang; Lori Friedman; Gregory D. Plowman; Timothy S. Heuer
- Web page: https://patentgrep.com/patent/US20030215849A1

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 1/485: {involving kinase}
- C12Q 1/527: involving lyase
- G01N 33/5017: {for testing neoplastic activity}
- G01N 33/573: for enzymes or isoenzymes
- G01N 33/575: for cancer
- G01N 33/57515: of the breast
- G01N 33/5752: of the lungs
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G01N 33/57545: of the ovaries
- G01N 33/57575: {involving oncogenic proteins}
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 33/57595: {involving intracellular compounds}
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G01N 2333/82: Translation products from oncogenes
- G01N 2333/90212: acting on a sulfur group of donors (1.8)
- G01N 2333/912: transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N 2333/988: Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2500/10: involving cells
- G01N 2510/00: Detection of programmed cell death, i.e. apoptosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Human PDPK1 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of PDPK1 are provided.

## Claims

### Claim 1

A method of identifying a candidate p53 pathway modulating agent, said method comprising the steps of:
(a) providing an assay system comprising a PDPK1 polypeptide or nucleic acid;
(b) contacting the assay system with a test agent under conditions whereby, but for the presence of the test agent, the system provides a reference activity; and
(c) detecting a test agent-biased activity of the assay system, wherein a difference between the test agent-biased activity and the reference activity identifies the test agent as a candidate p53 pathway modulating agent.

### Claim 2 (depends on 1)

The method of claim 1 wherein the assay system comprises cultured cells that express the PDPK1 polypeptide.

### Claim 3 (depends on 2)

The method of claim 2 wherein the cultured cells additionally have defective p53 function.

### Claim 4 (depends on 1)

The method of claim 1 wherein the assay system includes a screening assay comprising a PDPK1 polypeptide, and the candidate test agent is a small molecule modulator.

### Claim 5 (depends on 4)

The method of claim 4 wherein the assay is a kinase assay.

### Claim 6 (depends on 1)

The method of claim 1 wherein the assay system is selected from the group consisting of an apoptosis assay system, a cell proliferation assay system, an angiogenesis assay system, and a hypoxic induction assay system.

### Claim 7 (depends on 1)

The method of claim 1 wherein the assay system includes a binding assay comprising a PDPK1 polypeptide and the candidate test agent is an antibody.

### Claim 8 (depends on 1)

The method of claim 1 wherein the assay system includes an expression assay comprising a PDPK1 nucleic acid and the candidate test agent is a nucleic acid modulator.

### Claim 9 (depends on 8)

The method of claim 8 wherein the nucleic acid modulator is an antisense oligomer.

### Claim 10 (depends on 8)

The method of claim 8 wherein the nucleic acid modulator is a PMO.

### Claim 11 (depends on 1)

The method of claim 1 additionally comprising:
(d) administering the candidate p53 pathway modulating agent identified in (c) to a model system comprising cells defective in p53 function and, detecting a phenotypic change in the model system that indicates that the p53 function is restored.

### Claim 12 (depends on 11)

The method of claim 11 wherein the model system is a mouse model with defective p53 function.

### Claim 13

A method for modulating a p53 pathway of a cell comprising contacting a cell defective in p53 function with a candidate modulator that specifically binds to a PDPK1 polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:6, whereby p53 function is restored.

### Claim 14 (depends on 13)

The method of claim 13 wherein the candidate modulator is administered to a vertebrate animal predetermined to have a disease or disorder resulting from a defect in p53 function.

### Claim 15 (depends on 13)

The method of claim 13 wherein the candidate modulator is selected from the group consisting of an antibody and a small molecule.

### Claim 16 (depends on 1)

The method of claim 1, comprising the additional steps of:
(e) providing a secondary assay system comprising cultured cells or a non-human animal expressing PDPK1,
(f) contacting the secondary assay system with the test agent of (b) or an agent derived therefrom under conditions whereby, but for the presence of the test agent or agent derived therefrom, the system provides a reference activity; and
(g) detecting an agent-biased activity of the second assay system, wherein a difference between the agent-biased activity and the reference activity of the second assay system confirms the test agent or agent derived therefrom as a candidate p53 pathway modulating agent,
and wherein the second assay detects an agent-biased change in the p53 pathway.

### Claim 17 (depends on 16)

The method of claim 16 wherein the secondary assay system comprises cultured cells.

### Claim 18 (depends on 16)

The method of claim 16 wherein the secondary assay system comprises a nonhuman animal.

### Claim 19 (depends on 18)

The method of claim 18 wherein the non-human animal mis-expresses a p53 pathway gene.

### Claim 20

A method of modulating p53 pathway in a mammalian cell comprising contacting the cell with an agent that specifically binds a PDPK1 polypeptide or nucleic acid.

### Claim 21 (depends on 20)

The method of claim 20 wherein the agent is administered to a mammalian animal predetermined to have a pathology associated with the p53 pathway.

### Claim 22 (depends on 20)

The method of claim 20 wherein the agent is a small molecule modulator, a nucleic acid modulator, or an antibody.

### Claim 23

A method for diagnosing a disease in a patient comprising:
(a) obtaining a biological sample from the patient;
(b) contacting the sample with a probe for PDPK1 expression;
(c) comparing results from step (b) with a control;
(d) determining whether step (c) indicates a likelihood of disease.

### Claim 24 (depends on 23)

The method of claim 23 wherein said disease is cancer.
